Compare XRAY & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRAY | MLYS |
|---|---|---|
| Founded | 1899 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2008 | 2023 |
| Metric | XRAY | MLYS |
|---|---|---|
| Price | $9.73 | $26.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $14.58 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 4.7M | 880.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.58% | N/A |
| EPS Growth | 33.04 | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.85 | $12.59 |
| 52 Week High | $17.09 | $47.65 |
| Indicator | XRAY | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 24.31 | 40.36 |
| Support Level | N/A | $25.16 |
| Resistance Level | $13.06 | $31.12 |
| Average True Range (ATR) | 0.48 | 1.58 |
| MACD | -0.16 | -0.36 |
| Stochastic Oscillator | 12.55 | 6.90 |
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.